## Abstract A human monoclonal anti‐hepatitis B antibody preparation (TUVIRUMAB) was administered 6 times over a 2‐week period in a dose‐escalating scheme to chronic hepatitis B patients pre‐treated with lamivudine. The capacity of the TUVIRUMAB antibody to “neutralize” hepatitis B surface antigen
Lack of immune potentiation by complexing HBsAg in a heat-inactivated hepatitis B Vaccine with antibody in hepatitis B immunoglobulin
✍ Scribed by Dr. P. Nico Lelie; Peter J. A. J. van Amelsfoort; C. S. Martine de Groot; Ed Bakker; Wim Schaasberg; Jos C. M. Niessen; Henk W. Reesink
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 324 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
In a randomized, dose-response study among 305 health care workers, we examined whether the immunogenicity of a heat-inactivated hepatitis B vaccine could be enhanced when HBsAg was complexed by anti-HBs contained in hepatitis B immunoglobulin either at equivalent proportions or at 10-fold antigen excess. The dose of HBsAg in the control vaccine as well as in the two complexed vaccine preparations could be reduced from the standard value (3 pg) to 0.6 pg per injection without affecting the antibody response in the vaccinees. Still lower dosages of HBsAg in the three vaccine preparations induced significantly lower but comparable anti-HBs responses. These results indicate that, in man, using a heat-inactivated plasma vaccine, addition of anti-HBs contained in hepatitis B immunoglobulin does not potentiate the immunogenicity of HBsAg.
📜 SIMILAR VOLUMES
## Abstract It is important to monitor the long‐term persistence of antibodies induced by vaccination. Four cohorts were followed for their long‐term immunity after vaccination with a combined hepatitis A and B vaccine (Twinrix; SmithKline Beecham Biologicals, Rixsenart, Belgium). Two cohorts of ad